Ashley Ross

Ashley Ross

Auto-generated profile, based on publicly available information

Ashley Ross

Department of Psychiatry, University of Illinois Chicago, Chicago, Illinois

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2025 in Biological Psychiatry
Verified
Journal Article
Open access
ARAshley Ross
Ashley Ross
APAnna M. Patterson
Anna M. Patterson
TETory A. Eisenlohr-Moul
Tory A. Eisenlohr-Moul
Females of reproductive age experience more suicidal ideation, suicide attempts, and psychiatric hospitalizations than their male counterparts-with high risk during periods of hormonal transitions (e.g., puberty, the menstrual cycle, and pregnancy), suggesting a role for cyclical ovarian hormone fluctuations in suicide risk. This role is supported by cross-sectional and longitudinal studies showing that the menstrual cycle can trigger or exacerbate suicidal symptoms in susceptible individuals, particularly during the luteal and perimenstrual phases. However, brain-based mechanisms linking hormonal dynamics to suicidality remain underexplored. In hormone-sensitive individuals, normal fluctuations in estradiol (E2), progesterone (P4), and the neuroactive steroid allopregnanolone (ALLO) may disrupt the molecular mechanisms of mood regulation, cognitive processing, and behavioral control. This selective review synthesizes evidence across 6 promising molecular systems-serotonergic, GABAergic (gamma-aminobutyric acidergic), dopaminergic, neurotrophic, lipid, and DHEA(S) (dehydroepiandrosterone/dehydroepiandrosterone sulfate)-that are modulated by E2, P4, or ALLO and implicated in suicide pathophysiology. Drawing on neuroimaging, genetic, pharmacologic, and hormone manipulation studies, we describe potential mechanisms of cyclical suicide risk and their interactions with genetic and epigenetic vulnerability. Framed within the Dimensional Affective Sensitivity to Hormones across the Menstrual Cycle model, we outline the following research priorities: high-frequency within-person designs, hormone-informed neuroimaging, and personalized modeling approaches to identify modifiable, temporally precise mechanisms. Integrating menstrual cycle dynamics into suicide neuroscience may advance precision prevention for a large and underserved population.


20 August 2026 in SLEEP
Verified
Journal Article
Closed access
ANAnisha Nagpal
Anisha Nagpal
APAnna Patterson
Anna Patterson
ARAshley Ross
Ashley Ross
LKLoran Knol
Loran Knol
SSSajal Shukla
Sajal Shukla
TETory A Eisenlohr-Moul
Tory A Eisenlohr-Moul
Study Objectives: Sleep disturbance is closely linked to affective symptoms and suicidal ideation (SI). These symptoms fluctuate across the menstrual cycle; however, menstrual cycle–related sleep variability remains poorly characterized in psychiatric populations. This study examined how subjective and objective sleep fluctuate across the menstrual cycle in a psychiatric sample, considering individual differences and associations with negative affective and SI symptom trajectories. Materials and Methods: A transdiagnostic psychiatric sample recruited for recent suicidality provided intensive daily subjective sleep and symptom ratings (N = 142, M = 26.59 years, SD = 5.34) alongside wearable-derived (Oura) objective sleep measures (N = 39) across 1–3 menstrual cycles. Cycle timing was aligned to ovulation and menses using Phase-Aligned Cycle Time Scaling. Generalized additive mixed models quantified average cyclical effects and interindividual heterogeneity. Exploratory smooth mixture modeling (SMM) identified latent subgroups with shared temporal sleep trajectories which were compared to trait-level demographic and clinical characteristics as well as affective, SI, and pain cyclical symptom trajectory subgroups. Results: Most sleep outcomes showed substantial within-person cyclical variability. SMM identified distinct subgroups for Oura-derived sleep efficiency, and for subjective ratings of fatigue, insomnia, sleep quality, and hypersomnia, with patterns including perimenstrual or luteal worsening, as well as no cycle-related variability. Sleep subgroups, especially for subjective ratings, frequently significantly aligned with parallel affective, pain, and SI trajectories, suggesting temporally-coupled vulnerability. Conclusions: Sleep trajectories across the menstrual cycle are heterogeneous and meaningfully coupled with psychiatric symptom patterns. These findings support cycle-aware sleep monitoring and suggest that cyclical sleep disruption may help identify windows of heightened psychiatric risk, motivating replication and personalized intervention approaches.

11 November 2026 in medRxiv
Verified
Preprint
Open access
PDF file
TETory A. Eisenlohr-Moul
Tory A. Eisenlohr-Moul
ARAshley Ross
Ashley Ross
JPJessica R. Peters
Jessica R. Peters
ANAnisha Nagpal
Anisha Nagpal
KSKatja Schmalenberger
Katja Schmalenberger
MMMichelle Martel
Michelle Martel
Objective: Patients often describe menstrual-cycle worsening of attention-deficit/hyperactivity disorder (ADHD). We prospectively evaluated sample- and person-level cycle effects on ADHD symptoms and their independence from cyclical negative affect and pain. Methods: In an intensive longitudinal cohort (2019-2024), 106 naturally cycling adults meeting DSM-5 ADHD criteria on integrated assessment rated daily inattention and hyperactivity-impulsivity (Barkley Adult ADHD Rating Scale-IV), negative affect, and pain (median, 41 days) and provided daily salivary estradiol and progesterone for ovulation coding and phase-aligned cycle time (PACTS). Generalized additive models estimated sample-level and person-specific cycle curves; robust cyclicity was tested against each participant’s own time-shuffle null. Lab cognitive testing at four counterbalanced phases provided post hoc validation. Results: Sample-average cycle effects were significant yet small (<1% of daily variance), but 54% of 87 participants tested individually were robustly cyclical in ADHD symptoms (95% CI, 44%-64%; inattention 43%, hyperactivity-impulsivity 26%), more often with informant-confirmed ADHD (69% vs 36%). Among them, the cycle explained median 52% and 51% of symptom variance, a mean swing of 2.6 and 2.1 DSM-5 criteria. Most remained cyclical after adjustment for affect (68%) or pain (81%). Worsening most often peaked at and after menses rather than premenstrually; no cycle met prospective criteria for premenstrual dysphoric disorder (PMDD). Hormones did not differ by cyclicity. Conclusions: About half of these adults with ADHD showed robust cyclical symptom change, mostly not reducible to cyclical affect or pain and usually outside the premenstrual window. Future work should test its stability and whether a DSM-5 cyclical specifier is warranted.